Year: 2023

Appointment underscores Brookfield’s commitment to investing in financial infrastructure BROOKFIELD, NEWS, Oct. 23, 2023 (GLOBE NEWSWIRE) — Brookfield Asset Management (“Brookfield”) announced today the appointment of Sir Ron Kalifa as Vice Chair and Head of Financial Infrastructure investments. Ron brings a wealth of experience to his role at Brookfield, including over two decades of building and transforming businesses in the global payments space, and as a Non-Executive Director of the Bank of England’s Court of Directors. Brookfield’s financial infrastructure strategy focuses on identifying opportunities in digital assets and services that form the backbone of the global financial economy. The strategy typically seeks mature, high-quality companies that are integral components of the financial ecosystem and leverages Brookfield’s...

Partnership aims to include Aclarion’s Nociscan surgical decisioning technology within ATEC’s AlphaInformatiX platform to better inform spine surgery ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction Aclarion’s Nociscan is the first augmented intelligence platform to measure disc health biomarkers in the lumbar spine to help physicians identify the location of chronic low back pain BROOMFIELD, CO, Oct. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that the Company has executed a non-binding Letter...

STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 13, 2023, at 4:30 p.m. ET to report third quarter 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the Investors section of the Company’s website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical company leading a...

SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company’s corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial in to the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available...

LOS ANGELES, Oct. 23, 2023 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (Nasdaq: EGLX; TSX: EGLX) (the “Company”), the leading gaming media and entertainment company in North America, today announced that it has notified the Nasdaq Stock Market LLC (“Nasdaq”) of its intention to voluntarily delist its common shares (“Shares”) from Nasdaq. Shares will continue to trade on the Toronto Stock Exchange (“TSX”). As previously announced in its press release dated May 4, 2023, the Listing Qualifications department of Nasdaq approved the Company’s request for a 180-day extension (the “Extension”) to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). Although the Company has until October 30, 2023, to regain compliance with the Bid Price Rule, after careful consideration,...

AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population   AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that new data from the RINGSIDE study evaluating its lead investigational candidate AL102 for the treatment of desmoid tumors (DT) are being presented today at the European Society for Molecular Oncology (ESMO) Congress 2023, taking place October 20th to 24th in Madrid, Spain. The data are from Phase 2 (Part A) of the study and from the Open Label Extension (OLE). The results are featured in a poster being presented by Professor Robin Jones, Team...

TORONTO, Ontario and BROSSARD, Québec, Oct. 23, 2023 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ: BITF//TSX: BITF), a global vertically integrated Bitcoin mining company, fully energized the first phase of its farm in Baie-Comeau, Québec, increasing its total operating capacity to 240 MW and its hashrate to 6.3 EH/s. “By fully energizing Baie-Comeau, we increased our corporate operating capacity with cost-effective and clean hydro power and achieved our 6.3 EH/s goal,” said Bitfarms CEO Geoff Morphy. “This efficient facility leverages our operating and design expertise. We will continue to manage our balance sheet prudently to be positioned to capture growth opportunities both before and after the next Bitcoin halving, expected in mid-April 2024.” Bitfarms acquired Baie-Comeau in July 2023, with the plan to reach 11 MW by the end...

IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs. “We are pleased to welcome Dr. Katz to the Eledon team,” said David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer. “Dr. Katz brings a wealth of knowledge in the surgical transplantation field together with extensive experience designing and overseeing clinical trials for immunosuppressive treatments. We look forward to his leadership and contributions as we continue to advance tegoprubart for the prevention of rejection in patients undergoing transplantation procedures.” Dr. Katz is an experienced transplant surgeon with significant clinical development experience....

CALGARY, Alberta, Oct. 23, 2023 (GLOBE NEWSWIRE) — Global Helium Corp. (“HECO” or the “Company”) (CSE: HECO, OTC: HECOF) is pleased to announce closing of the first tranche of its previously announced non-brokered private placement offering, raising aggregate gross proceeds of CAD$3,529,750 (the “Offering”). By way of the Offering, HECO issued 970,000 Series A Preferred Shares at a price of CAD$0.25 per unit (defined below) to Canadian residents and 13,162,162 Series A Preferred Shares at US$0.185 per share to US residents. The Company shall pay a dividend on the principal amount of each outstanding Preferred Share in the amount of 10% per annum starting from the date of issuance until the earlier of the date of conversion or the fifth anniversary of the date of issuance (the “Maturity Date”)....